IPO registrations (S-1, F-1) · Registrants
Outlook Therapeutics, Inc.
- SEC CIK
- 1649989 · filings on EDGAR ↗
- Former names
- Oncobiologics, Inc. (2015–2018)
- Registration
- Form S-1, first filed 2016-01-15, last 2020-04-08; 6 initial registrations, 9 amendments
- Outcome
- Final prospectus filed 2016-05-13; declared effective 2016-05-12
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- DE
- Business address
- 111 S. WOOD AVENUE, UNIT #100, Iselin, NJ 08830
- EIN
- 38-3982704
- Ticker
- OTLK (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Outlook Therapeutics, Inc. on the corporate pages
Offering terms
- Final price
- $6.00 per share (424B4 filed 2016-05-13, an initial public offering)
- Shares sold
- 5,833,334
- Gross proceeds
- $35,000,004 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol ONSIU
- Lead underwriters
- Jefferies; Barclays
- Syndicate
- Cantor Fitzgerald
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: OUTLOOK THERAPEUTICS, INC. Fuzzy (name and state)
- Form 5500 plan sponsor: OUTLOOK THERAPEUTICS INC EXACT (EIN (EXACT))
- Form D issuer: Outlook Therapeutics, Inc. EXACT (CIK (EXACT))
- SEC filer: Oncobiologics, Inc. EXACT (CIK (EXACT))
Filings 33
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2016-01-15 | S-1 | S-1 (registration) | Oncobiologics, Inc. | 0001571049-16-010787 ↗ |
| 2016-02-12 | S-1/A | S-1/A (amendment) | Oncobiologics, Inc. | 0001571049-16-011706 ↗ |
| 2016-02-26 | S-1/A | S-1/A (amendment) | Oncobiologics, Inc. | 0001571049-16-012194 ↗ |
| 2016-04-27 | S-1/A | S-1/A (amendment) | Oncobiologics, Inc. | 0001571049-16-014288 ↗ |
| 2016-05-04 | S-1/A | S-1/A (amendment) | Oncobiologics, Inc. | 0001571049-16-014796 ↗ |
| 2016-05-11 | S-1/A | S-1/A (amendment) | Oncobiologics, Inc. | 0001571049-16-015098 ↗ |
| 2016-05-12 | EFFECT | EFFECT (declared effective) | Oncobiologics, Inc. | 9999999995-16-004632 ↗ |
| 2016-05-13 | 424B4 | 424B4 (final prospectus) | Oncobiologics, Inc. | 0001571049-16-015284 ↗ |
| 2016-06-30 | S-1 | S-1 (registration) | Oncobiologics, Inc. | 0001571049-16-016401 ↗ |
| 2016-07-14 | EFFECT | EFFECT (declared effective) | Oncobiologics, Inc. | 9999999995-16-005155 ↗ |
| 2017-01-13 | EFFECT | EFFECT (declared effective) | Oncobiologics, Inc. | 9999999995-17-000094 ↗ |
| 2017-01-13 | EFFECT | EFFECT (declared effective) | Oncobiologics, Inc. | 9999999995-17-000114 ↗ |
| 2017-02-15 | S-1 | S-1 (registration) | Oncobiologics, Inc. | 0001571049-17-001399 ↗ |
| 2017-02-27 | EFFECT | EFFECT (declared effective) | Oncobiologics, Inc. | 9999999995-17-000442 ↗ |
| 2017-03-10 | S-1 | S-1 (registration) | Oncobiologics, Inc. | 0001571049-17-002293 ↗ |
| 2017-03-22 | EFFECT | EFFECT (declared effective) | Oncobiologics, Inc. | 9999999995-17-000631 ↗ |
| 2018-02-23 | EFFECT | EFFECT (declared effective) | Oncobiologics, Inc. | 9999999995-18-000486 ↗ |
| 2018-02-23 | EFFECT | EFFECT (declared effective) | Oncobiologics, Inc. | 9999999995-18-000487 ↗ |
| 2018-02-28 | EFFECT | EFFECT (declared effective) | Oncobiologics, Inc. | 9999999995-18-000516 ↗ |
| 2018-03-30 | EFFECT | EFFECT (declared effective) | Oncobiologics, Inc. | 9999999995-18-000719 ↗ |
| 2019-02-21 | S-1 | S-1 (registration) | Outlook Therapeutics, Inc. | 0001144204-19-009191 ↗ |
| 2019-02-27 | EFFECT | EFFECT (declared effective) | Outlook Therapeutics, Inc. | 9999999995-19-000330 ↗ |
| 2019-03-07 | S-1/A | S-1/A (amendment) | Outlook Therapeutics, Inc. | 0001144204-19-012648 ↗ |
| 2019-03-19 | S-1/A | S-1/A (amendment) | Outlook Therapeutics, Inc. | 0001144204-19-014735 ↗ |
| 2019-04-02 | S-1/A | S-1/A (amendment) | Outlook Therapeutics, Inc. | 0001144204-19-017715 ↗ |
| 2019-04-09 | S-1/A | S-1/A (amendment) | Outlook Therapeutics, Inc. | 0001144204-19-018747 ↗ |
| 2019-04-09 | EFFECT | EFFECT (declared effective) | Outlook Therapeutics, Inc. | 9999999995-19-000647 ↗ |
| 2019-04-10 | S-1MEF | S-1MEF (added securities) | Outlook Therapeutics, Inc. | 0001144204-19-018964 ↗ |
| 2019-04-10 | 424B4 | 424B4 (final prospectus) | Outlook Therapeutics, Inc. | 0001144204-19-019089 ↗ |
| 2019-06-26 | EFFECT | EFFECT (declared effective) | Outlook Therapeutics, Inc. | 9999999995-19-001451 ↗ |
| 2020-04-08 | S-1 | S-1 (registration) | Outlook Therapeutics, Inc. | 0001104659-20-044699 ↗ |
| 2020-04-17 | EFFECT | EFFECT (declared effective) | Outlook Therapeutics, Inc. | 9999999995-20-000784 ↗ |
| 2021-04-01 | EFFECT | EFFECT (declared effective) | Outlook Therapeutics, Inc. | 9999999995-21-001261 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2016-05-11 | S-1/A | registration statement | $29.05 | 5,833,334 | $169,458,352 | Nasdaq ONS | 3 | primary document; price line, shares headline, proceeds computed, cover names 3 | document ↗ | |
| 2016-05-13 | 424B4 | final prospectus | $6.00 | 5,833,334 | $35,000,004 | Nasdaq ONSIU | 3 | primary document; price sentence, shares headline, proceeds table, cover names 3 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Bahrt Kenneth | Officer | Chief Medical Officer | 7 | 2016–2019 | |
| Bao Kogan | Officer | VP, Analytical Sciences | 2 | 2016 | |
| Brady Todd C | Director | 4 | 2016–2017 | ||
| Canute Scott A | Director | 6 | 2016–2017 | ||
| Dyrness Albert D. | Director | 3 | 2016–2017 | ||
| Gangloff Scott A. | Officer | SVP, Development & Mfrg | 3 | 2016 | |
| Griffith Donald J. | Director | 3 | 2016 | ||
| HILZINGER KURT J | Director | 36 | 2016–2026 | ||
| KENYON LAWRENCE A | Director,Officer; Officer | CEO, Pres, CFO, Treas & Secy; CFO and Secretary; Chief Financial Officer; CHIEF FINANCIAL OFFICER | 19 | 2016–2026 | |
| MCANDREW STEPHEN J | Officer | SVP Bus. Strat. & Dev. | 6 | 2016–2018 | |
| Mohan Pankaj | Director,Officer,TenPercentOwner; Director,TenPercentOwner | President & CEO | 7 | 2016–2019 | |
| Smith Hoke Robin | Director | 2 | 2016 | ||
| Yamashita Elizabeth A. | Officer | VP, Regulatory Affairs | 4 | 2016–2017 | |
| BioLexis Pte Ltd. | Director,Officer,TenPercentOwner; Director,TenPercentOwner; TenPercentOwner | Chief Executive Officer | 22 | 2017–2022 | |
| Sukhtian Faisal Ghiath | Director; Director,TenPercentOwner | 30 | 2017–2026 | ||
| Thomas Joe | Director | 3 | 2017–2019 | ||
| Pillai Arun Kumar | Director,TenPercentOwner; TenPercentOwner | 21 | 2017–2022 | ||
| Sukhtian Ghiath M. | Director,TenPercentOwner | 26 | 2017–2026 | ||
| Albrecht Claudio | Director | 2 | 2017 | ||
| Haddadin Yezan Munther | Director | 24 | 2017–2026 | ||
| Windisch Joerg | Director | 4 | 2018 | ||
| THURMAN RANDY H | Director | 19 | 2018–2026 | ||
| Dagnon Terry | Officer | Chief Operating Officer; Chief Operations Officer | 11 | 2018–2023 | |
| Evanson Jeff | Officer | Chief Commercial Officer; CHIEF COMMERCIAL OFFICER | 12 | 2018–2024 | |
| GMS Ventures & Investments | Director; Director,TenPercentOwner | 15 | 2020–2026 | ||
| Auffarth Gerd | Director | 14 | 2020–2025 | ||
| Gangolli Julian S | Director | 14 | 2020–2025 | ||
| Syntone Ventures LLC | TenPercentOwner | 4 | 2020–2024 | ||
| Huang Andong | Director | 14 | 2020–2025 | ||
| TRENARY C RUSSELL III | Director,Officer | CEO and President; CEO AND PRESIDENT | 8 | 2021–2024 | |
| Haller Julia A | Director | 8 | 2022–2025 | ||
| Jahr Robert Charles | Director,Officer; Officer | Chief Executive Officer | 4 | 2025–2026 | |
| Lundquist Kevin Michael | Officer | Chief Financial Officer | 2 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2026-05-07 | Outlook Therapeutics, Inc. | Biotechnology | $5,000,000 | $0 | 2 | 1 |
| 2025-01-27 | Outlook Therapeutics, Inc. | Biotechnology | $31,977,359 | $0 | 10 | 1 |
| 2024-04-16 | Outlook Therapeutics, Inc. | Biotechnology | $13,250,005 | $5,000,002 | 1 | 1 |
| 2024-03-29 | Outlook Therapeutics, Inc. | Biotechnology | $159,000,000 | $60,000,000 | 21 | 1 |
| 2023-01-06 | Outlook Therapeutics, Inc. | Biotechnology | $31,820,000 | $31,820,000 | 1 | 1 |
| 2023-01-06 | Outlook Therapeutics, Inc. | Biotechnology | $1,031,510 | $1,031,510 | 1 | 1 |
| 2021-02-12 | Outlook Therapeutics, Inc. | Biotechnology | $4,013,627 | $4,013,627 | 2 | 1 |
| 2020-06-09 | Outlook Therapeutics, Inc. | Biotechnology | $16,000,000 | $16,000,000 | 1 | 1 |
| 2020-03-11 | Outlook Therapeutics, Inc. | Other | $7,971,155 | $7,971,155 | 7 | 1 |
| 2017-09-25 | Oncobiologics, Inc. | Other | $40,075,000 | $3,262,800 | 1 | 1 |
| 2015-12-23 | Oncobiologics, Inc. | Other | $50,000,000 | $6,345,960 | 11 | 1 |
| 2015-10-13 | Oncobiologics, Inc. | Other | $14,480,486 | $14,480,486 | 4 | 1 |
| 2015-08-10 | Oncobiologics, Inc. | Other | $31,050,000 | $31,050,000 | 7 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | OUTLOOK THERAPEUTICS, INC. | NJ | State business registries | name and state |
| Form D issuer | Outlook Therapeutics, Inc. | NJ | Form D private offerings | CIK (EXACT) |
| Patent assignee | Outlook Therapeutics, Inc. | NJ | Patents (USPTO) | name and state |
| SEC filer | Outlook Therapeutics, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Outlook Therapeutics, Inc. | NJ | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | OUTLOOK THERAPEUTICS INC | EIN (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.